Clay Siegall has an ambition of revolutionizing the field of oncology through Seattle Genetics.

May 9, 2018
By Rel

Clay Siegall has an ambition of revolutionizing the field of oncology through Seattle Genetics.

Clay Siegall is the founder, President, and chief executive officer for Seattle Genetics a company that was founded in 1998. Clay Siegall is also the chairman of the board of directors of the Seattle Genetics. Clay Siegall has overseen the success of the company with some antibody-based therapies for cancer which include ADCETRIS that was certified by the Food and Drug Administration (FDA) in the year 2011. Adcetris was the first drug for the company to be FDA approved. The drug is a treatment for Hodgkin lymphoma that affects the lymph system and also has a possibility for spreading to other organs of the body. Seattle Genetics has been focused on studying and doing research on human antibodies and in the end creating therapies and drugs for the treatment of patients. Seattle Genetics has revived hope in the biotech community of Seattle through its research on developing an antibody that destroys the cancerous cells by delivering a toxic payload from the inside. Seattle Genetics is ranked as one of the largest biotech firms with an estimated market value of over $10 billion and has more than 900 workers. The organization looks forward to advancing to a leading pharmaceutical company. The firm has focused their funds on research and marketing strategies and will be having additional 200 employees in their portfolio. Clay Siegall is confident that the organization will grow to become a global company that deals with a variety of healthcare products in the field of oncology. He is also proud of the efforts of the Seattle Genetics team having some drugs in its pipeline and is motivated to take Seattle Genetics to achieve greater heights. Clay Seigall is also determined to transform his company into a dynamic company that does not only focus on developing drugs but also has the capabilities of marketing their new drugs on the global platform. Clay Siegall has opened a branch of offices in Switzerland that would facilitate Seattle Genetics to carry out their global marketing. The company’s shares have gone up since the year 2014, and in 3 years, the company’s stock prices have more than tripled from $20 a share to $66. Despite the uncertainties both in the economic and political arenas Clay Siegall is determined with his fight against cancer and bringing Seattle Genetics into the big leagues as a drug development company.